Monstelo

ANTM = REVERSAL UPWARDS HAPPENING / DETAILED REPORT / TP: $294

Long
NYSE:ANTM   None
ANTM has established support at $284 and if you look at the graph. Each green line shows a support level. The first resistance level is at $294. If it breaks the resistance level then it will easily pass $300. The technical analysis pattern is a BULL FLAG and is trending upwards. It's most recent support level is at $284. Volume is staring to increase which makes the indicator stronger. The MACD indicator is about to crossover leading an indication of upwards momentum.

Fundamental Analysis:
Liabilities in 2017 are 44,037 (in millions) while in 2018 are 43,030 (in millions). They are decreasing liabilities and increasing total assets which are 70,540 (In millions) in 2017 while in 2018 are 71,571 (In millions). At least in the balance sheet they are doing a decent job at maintaining profitable which can be seen the number of times they have beat earnings. Cash flow are growing steady which is another indication in terms of fundamental analysis this company will continue to grow. Short Interest is 1.72% which is good for the bullish investors. The Beta is 0.7 which produces less volatility then SPX .

Based on my Research using the BLOOMBERG TERMINAL; The fundamentals are strong and projections for earnings this JULY. The company will most likely beat earnings again. ANR (Analyst Recommendations) Based on this function, the 12 month TARGET PRICE is $335. There is 20 BUYS , 4 HOLDS, and 0 SELLS. Every analyst in the system has Target Prices higher than $300 and companies include but are not limited to Wells Fargo, Morning star, RBC Capital Markets, Cowen, Wolfe Research, etc.

INSIDER PURCHASE:

Norwood Felicia F ; Exec VP & President made a purchase of common stock on 7/2/2019. She bought 176 shares @ $280.66 bringing her to a total of 3,843 shares. The report (SEC FORM 4) was released to the public on 7/5/2019.














Tags: Anthem, ANTM, TSLA, APPL, GOO, BTC, LTC, Bitcoin, Blue Cross
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.